stockportfolio.pro
Revvity, Inc. (RVTY)
Healthcare · Diagnostics & Research · NYSE
Revvity, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2017 | 2018 | 2019 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.12B | $2.26B | $2.78B | $2.88B | $3.78B | $3.83B | $4.61B | $2.75B | $2.76B | $2.86B |
| Gross profit | $1.01B | $1.07B | $1.34B | $1.40B | $2.11B | $2.43B | $1.99B | — | — | — |
| Net income | $234.30M | $292.63M | $237.93M | $227.56M | $727.89M | $943.16M | $579.18M | $693.09M | $270.38M | $241.20M |
| Net margin | 11.1% | 13.0% | 8.6% | 7.9% | 19.2% | 24.6% | 12.6% | 25.2% | 9.8% | 8.4% |
Source: Revvity, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into RVTY stock?
At today's market cap of $11.62B, Revvity, Inc. is priced for free-cash-flow growth of about 9.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $509.41M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -9.3%/yr over the last five fiscal years and revenue -5.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Revvity, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RVTY in your portfolio →
Revvity, Inc. financial history by metric
About Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Revvity, Inc. — frequently asked questions
What is Revvity, Inc.'s revenue?
Revvity, Inc. (RVTY) reported revenue of $2.86B for fiscal year 2025, up 3.6% from the prior year, according to its SEC filings.
Is Revvity, Inc. profitable?
Yes. RVTY earned net income of $241.20M in fiscal 2025, a net margin of 8.4%.
What is RVTY's P/E ratio?
Revvity, Inc. trades at a price-to-earnings ratio of about 50.1 based on the latest data in our nightly-refreshed cache.
How fast is Revvity, Inc. growing?
RVTY's revenue grew at roughly -5.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Revvity, Inc. have?
As of fiscal year 2025, RVTY carried roughly $2.63B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Revvity, Inc.'s market cap?
Revvity, Inc. (RVTY) has a market capitalization of about $11.62B, based on the latest data in our nightly-refreshed cache.
When does Revvity, Inc.'s fiscal year end?
RVTY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into RVTY stock?
At today's market cap of $11.62B, Revvity, Inc. is priced for free-cash-flow growth of about 9.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $509.41M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -9.3%/yr over the last five fiscal years and revenue -5.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Revvity, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.